Back1Optimizing TROP-2 ADC Integration in NSCLC: Evolving Evidence, Safety Management, and Sequencing in a Changing Treatment Landscape
Step 1 of 2
Downloadable slides on the evolving role of TROP-2–directed antibody–drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC), including recent clinical trial evidence, biomarker development, treatment sequencing, and adverse event management. The slides review differences in the mechanisms of action and safety profiles of datopotamab deruxtecan, sacituzumab govitecan, and sacituzumab tirumotecan, along with efficacy and safety findings from pivotal and emerging trials, including TROPION-Lung01/02/05, EVOKE-01/02, and OptiTROP-Lung01, 03, 04, and 05. Data are examined across patient subgroups defined by histology, EGFR mutation status, PD-L1 expression, and prior treatment, with consideration of approved indications, investigational combinations, and emerging TROP-2 biomarker approaches. The slides also address practical strategies for preventing, monitoring, and managing ADC-associated toxicities, including stomatitis, ocular adverse events, neutropenia, diarrhea, and interstitial lung disease/pneumonitis, providing clinical context for individualized treatment selection, sequencing, and supportive care in advanced NSCLC.
